Cargando…

Pyroptosis and inflammasomes in cancer and inflammation

Nonprogrammed cell death (NPCD) and programmed cell death (PCD) are two types of cell death. Cell death is significantly linked to tumor development, medication resistance, cancer recurrence, and metastatic dissemination. Therefore, a comprehensive understanding of cell death is essential for the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jie‐Lin, Hua, Sheng‐Ni, Bao, Hai‐Juan, Yuan, Jing, Zhao, Yang, Chen, Shuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518439/
https://www.ncbi.nlm.nih.gov/pubmed/37752941
http://dx.doi.org/10.1002/mco2.374
_version_ 1785109513886498816
author Wang, Jie‐Lin
Hua, Sheng‐Ni
Bao, Hai‐Juan
Yuan, Jing
Zhao, Yang
Chen, Shuo
author_facet Wang, Jie‐Lin
Hua, Sheng‐Ni
Bao, Hai‐Juan
Yuan, Jing
Zhao, Yang
Chen, Shuo
author_sort Wang, Jie‐Lin
collection PubMed
description Nonprogrammed cell death (NPCD) and programmed cell death (PCD) are two types of cell death. Cell death is significantly linked to tumor development, medication resistance, cancer recurrence, and metastatic dissemination. Therefore, a comprehensive understanding of cell death is essential for the treatment of cancer. Pyroptosis is a kind of PCD distinct from autophagy and apoptosis in terms of the structure and function of cells. The defining features of pyroptosis include the release of an inflammatory cascade reaction and the expulsion of lysosomes, inflammatory mediators, and other cellular substances from within the cell. Additionally, it displays variations in osmotic pressure both within and outside the cell. Pyroptosis, as evidenced by a growing body of research, is critical for controlling the development of inflammatory diseases and cancer. In this paper, we reviewed the current level of knowledge on the mechanism of pyroptosis and inflammasomes and their connection to cancer and inflammatory diseases. This article presents a theoretical framework for investigating the potential of therapeutic targets in cancer and inflammatory diseases, overcoming medication resistance, establishing nanomedicines associated with pyroptosis, and developing risk prediction models in refractory cancer. Given the link between pyroptosis and the emergence of cancer and inflammatory diseases, pyroptosis‐targeted treatments may be a cutting‐edge treatment strategy.
format Online
Article
Text
id pubmed-10518439
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105184392023-09-26 Pyroptosis and inflammasomes in cancer and inflammation Wang, Jie‐Lin Hua, Sheng‐Ni Bao, Hai‐Juan Yuan, Jing Zhao, Yang Chen, Shuo MedComm (2020) Reviews Nonprogrammed cell death (NPCD) and programmed cell death (PCD) are two types of cell death. Cell death is significantly linked to tumor development, medication resistance, cancer recurrence, and metastatic dissemination. Therefore, a comprehensive understanding of cell death is essential for the treatment of cancer. Pyroptosis is a kind of PCD distinct from autophagy and apoptosis in terms of the structure and function of cells. The defining features of pyroptosis include the release of an inflammatory cascade reaction and the expulsion of lysosomes, inflammatory mediators, and other cellular substances from within the cell. Additionally, it displays variations in osmotic pressure both within and outside the cell. Pyroptosis, as evidenced by a growing body of research, is critical for controlling the development of inflammatory diseases and cancer. In this paper, we reviewed the current level of knowledge on the mechanism of pyroptosis and inflammasomes and their connection to cancer and inflammatory diseases. This article presents a theoretical framework for investigating the potential of therapeutic targets in cancer and inflammatory diseases, overcoming medication resistance, establishing nanomedicines associated with pyroptosis, and developing risk prediction models in refractory cancer. Given the link between pyroptosis and the emergence of cancer and inflammatory diseases, pyroptosis‐targeted treatments may be a cutting‐edge treatment strategy. John Wiley and Sons Inc. 2023-09-24 /pmc/articles/PMC10518439/ /pubmed/37752941 http://dx.doi.org/10.1002/mco2.374 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reviews
Wang, Jie‐Lin
Hua, Sheng‐Ni
Bao, Hai‐Juan
Yuan, Jing
Zhao, Yang
Chen, Shuo
Pyroptosis and inflammasomes in cancer and inflammation
title Pyroptosis and inflammasomes in cancer and inflammation
title_full Pyroptosis and inflammasomes in cancer and inflammation
title_fullStr Pyroptosis and inflammasomes in cancer and inflammation
title_full_unstemmed Pyroptosis and inflammasomes in cancer and inflammation
title_short Pyroptosis and inflammasomes in cancer and inflammation
title_sort pyroptosis and inflammasomes in cancer and inflammation
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10518439/
https://www.ncbi.nlm.nih.gov/pubmed/37752941
http://dx.doi.org/10.1002/mco2.374
work_keys_str_mv AT wangjielin pyroptosisandinflammasomesincancerandinflammation
AT huashengni pyroptosisandinflammasomesincancerandinflammation
AT baohaijuan pyroptosisandinflammasomesincancerandinflammation
AT yuanjing pyroptosisandinflammasomesincancerandinflammation
AT zhaoyang pyroptosisandinflammasomesincancerandinflammation
AT chenshuo pyroptosisandinflammasomesincancerandinflammation